Evommune, Inc. is a clinical-stage biotechnology company headquartered in Palo Alto, California, that develops therapies targeting key drivers of chronic inflammatory diseases. Its initial clinical programs focus on chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The company's lead assets include EVO756, which has been evaluated in CSU and AD, and EVO301, an investigational therapy in development for AD and UC. More recently, Evommune in-licensed EVO570, an oral VAV1 molecular glue degrader, to expand its immunology pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Because the company is pre-revenue and development-stage, investors follow Evommune primarily for its clinical data readouts, pipeline execution, and cash runway rather than current financial results. The stock's valuation is highly sensitive to trial outcomes and to the market's assessment of its probability of regulatory and commercial success.
Over the past 30 days, Evommune shares have rebounded sharply, rising approximately 37% from a close near $5.17 to roughly $7.07. The move marked a recovery from multi-month lows and was accompanied by a significant pickup in trading volume during key sessions, including a pronounced rally in late October when shares surged from about $5.16 to above $6.30 in a single session.
The longer-term quarterly picture is more mixed. Entering the period in late August around $13.48, the stock declined roughly 47% through late November, reflecting the heavy selloff in September after disappointing trial data. In other words, the recent 30-day advance represents a partial, and still fragile, recovery within a broader multi-month downtrend. Over the past 52 weeks, the stock remains down by more than half.
The primary catalyst behind the 30-day rebound was renewed confidence in the company's pipeline. In September, Evommune disclosed negative results from a Phase 2b trial of EVO756 in atopic dermatitis, following an earlier miss in chronic spontaneous urticaria, which triggered a wave of analyst price-target reductions and pushed shares toward their 52-week low.
Sentiment began to stabilize as the company shifted investor focus to EVO301. Additional Phase 2a proof-of-concept data for EVO301 in moderate-to-severe atopic dermatitis were presented at the European Academy of Dermatology and Venereology (EADV) Congress, and several analysts framed the asset as a credible emerging candidate. In early November, Evommune announced an agreement to in-license EVO570 from Hinova Pharmaceuticals, along with a $30 million private placement priced at $6.04 per share, extending its expected cash runway. UBS also initiated coverage with a Neutral rating and an $8 price target, while Morgan Stanley lowered its target to $23 from $26 but maintained an Overweight rating.
The dominant event of the past quarter was the September clinical setback for EVO756. The Phase 2b failure in atopic dermatitis, combined with the earlier CSU disappointment, removed a key near-term value driver from the company's lead program and prompted multiple firms to cut their price targets. This drove the stock from the mid-teens toward single digits and kept sentiment cautious through much of October.
Against that backdrop, the company's strategy shifted toward diversifying and de-risking its portfolio. Positive EVO301 proof-of-concept data, the EVO570 in-licensing, and the accompanying financing helped reframe the narrative around a broader immunology platform with multiple shots on goal. The quarterly trend therefore reflects a sharp de-rating followed by an early-stage stabilization and recovery effort.
Looking ahead, the key catalysts for Evommune are clinical milestones rather than near-term financial results. Investors should monitor the progression of EVO301 into later-stage studies in atopic dermatitis and ulcerative colitis, as well as early data from the newly added EVO570 program, with Phase 1 results and a rheumatoid arthritis Phase 2 study anticipated over the coming years. Additional data readouts across the pipeline, including planned EVO756 work in migraine, will also shape sentiment. From what I see, this is important because biotech valuations often hinge on these inflection points.
On the financial side, cash runway, capital-raising activity, and any changes to analyst price targets and ratings remain important. Because the company is pre-revenue, quarterly losses are expected, but the pace of cash burn and the timing of future financings can influence share price. Broader biotech sentiment, interest-rate conditions, and investor risk appetite for clinical-stage names are additional factors that may affect valuation independently of company-specific news. I’m watching this closely as the next readouts approach.
In my analysis, I often turn to Tickeron’s AI Pattern Search Engine to quickly review technical setups in names like this. It provides a useful way to scan for patterns across the market and helps put price action into context alongside the fundamental developments. The tool has become a regular part of how I evaluate opportunities in the biotech space.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Oscillator for EVMN moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 2 instances where the indicator moved out of the overbought zone. In 2 of the 2 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
EVMN moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EVMN broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on EVMN as a result. In 13 of 17 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for EVMN just turned positive on October 19, 2026. Looking at past instances where EVMN's MACD turned positive, the stock continued to rise in 4 of 6 cases over the following month. The odds of a continued upward trend are 67%.
The 10-day moving average for EVMN crossed bullishly above the 50-day moving average on November 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +12.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVMN advanced for three days, in 33 of 41 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 16 of 26 cases where EVMN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.869) is normal, around the industry mean (3.596). P/E Ratio (-0.562) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (34.014) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. EVMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology